There is an urgent need to identify an effective therapeutic strategy against COVID-19 by targeting and suppressing excessive mediators of complements in controlling SARS-CoV-2 infection, as well as pro-inflammatory cytokines (IL1-β, IL-6, and TNF-α) and chemokines (IL-8 and RANTES) that might be used as predictive markers to evaluate disease severity and, thus, can be targeted as treatment options in COVID-19 disease. The gene discussed is CXCL8; the disease is COVID-19.